Conversion hepatectomy for unresectable hepatocellular carcinoma: Principles of patient selection and surgical decision-making
In brief
Resection after systemic therapy shows survival benefit signal in selected HCC patients
In the TALENTOP phase 3 trial, patients with unresectable hepatocellular carcinoma who achieved an R0 resection after induction therapy experienced a favorable overall-survival signal compared with continued medical treatment, although the data are still immature. The authors propose a 5-D framework to identify which responders truly merit conversion hepatectomy, emphasizing tumor biology, depth and durability of response, complete clearance, liver reserve, and timing.
- Journal
- Bioscience trends (Q1)
- Published
- 10 September 2026
- Study design
- Non-randomized / quasi-experimental trial
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Jiayun Ge, Fan Yang, Yanling Chen, Haijie Hong, Wei Tang
- PMID
- 42716789
- DOI
- 10.5582/bst.2026.01229
Why clinicians should know about it
- Picked for Surgical Oncology (paper of the day, 11 September 2026): Conversion hepatectomy after systemic therapy, surgical decision-making
Abstract
Modern systemic regimens have increased objective response in unresectable hepatocellular carcinoma (HCC), producing a small but clinically important population in whom curative-intent local treatment can be considered. And yet response is not synonymous with resectability, and resectability is not synonymous with an indication for hepatectomy. This review begins at the point of making a post-response decision rather than ranking conversion regimens or proposing a general framework for longitudinal treatment sequencing. We separate technical, liver-functional, and oncological unresectability and propose a 5D framework-Disease extent and biology, Depth and durability of response, Definitive disease clearance, Durable liver reserve, and Decision timing-to distinguish patients who merely respond from those for whom resection is both feasible and rational. Retrospective series support feasibility and occasionally durable disease control in selected patients. The TALENTOP phase 3 trial now provides the first randomized comparative signal favoring resection in a narrowly defined post-induction population already judged suitable for R0 resection; however, overall survival remains immature, and the trial has not demonstrated a general causal survival benefit for all responders. The next phase of research should therefore validate reproducible decision rules, prespecify resectability assessments, and anchor analyses to the time surgical eligibility is achieved. Conversion hepatectomy should be understood not as a strict requirement after tumor shrinkage but as an irreversible switch in treatment justified by concordant tumor biology, depth and durability of response, complete disease clearance, hepatic safety, and superiority over available alternatives.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.